It was good news for generic drug firms such as Allergan (AGN) and Mylan (MYL), as pharma giant Pfizer (PFE) lost a
Categories
Health Care
Cronos reports loss in 3Q despite strong revenue growth
Cannabis producer Cronos Group (CRON) revenues jumped 186% to CAD3.76 million for the third quarter 2018, aided by strong sales growth of
Earnings preview: Tilray stock might see big fluctuations post Q3 results
It can be safely said that cannabis is this year’s bitcoin – be it the debates surrounding its regulation or the immense
AstraZeneca Q3 profit dips 37% but beats estimates
AstraZeneca Plc (AZN) reported a 37% dip in earnings for the third quarter due to lower revenue, a decline in gross margin
Cardinal Health posts better-than-expected Q1 earnings
Cardinal Health Inc. (CAH) reported a 408% jump in earnings for the first quarter helped by a gain on disposal of naviHealth
The ‘midterm’ shot sends cannabis stocks to a new high
The midterm election has brought cheer to companies doing marijuana-related businesses in the US, despite the uncertainties surrounding regulation of cannabis in
Regeneron beats market estimates on Q3 revenue and profits
Regeneron Pharmaceuticals Inc. (REGN) surpassed market expectations on revenue and earnings for the third quarter of 2018. The stock was up over
Mallinckrodt soars 10% on strong Q3
Pharmaceutical company Mallinckrodt plc (MNK) Tuesday reported third-quarter results that topped analysts’ estimates, sending its shares up 10% during pre-market hours. Earnings
Bausch Health stock gains after Q3 revenues beat street view
Bausch Health Companies (BHC) reported a net loss for the third quarter, compared to a profit last year. On an adjusted basis,
CVS Health Corp beats Street estimates five quarters in a row, stock jumps
CVS Health Corp (CVS) posted earnings results for the third quarter of 2018 on Tuesday, November 6, before the opening bell. Net
Mylan posts better-than-expected Q3 profit
Global pharmaceutical company Mylan N.V. (MYL) reported 100% surge in earnings for the third quarter helped by lower costs and expenses as
European competition threatens AbbVie’s run of top-selling Humira
US pharma giant AbbVie Inc (ABBV) cut its overseas sales forecast on Friday for its offering Humira, on expected pricing cuts to
AbbVie Q3 profit jumps 68%, beats estimates
AbbVie Inc. (ABBV) reported a 68% jump in earnings for the third quarter helped by sales growth from Humira, Imbruvica, and HCV.
Cigna stock rises on upbeat Q3 results
Cigna Corp. (CI) reported a 38% jump in earnings for the third quarter as continued strong business growth in its Global Health
Teva’s shares soar on better-than-expected Q3 results and higher guidance
Teva Pharmaceutical Industries Ltd. (TEVA) saw its stock gain over 6.8% during premarket hours on Thursday after the company surpassed expectations on